News
TKPHF
28.70
NaN%
--
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 15h ago
Leerink says Takeda results signal positive readthrough for Alumis
TipRanks · 2d ago
Alumis price target raised to $20 from $14 at H.C. Wainwright
TipRanks · 2d ago
Takeda's Phase 3 Study Of Oral Zasocitinib In Plaque Psoriasis Achieves Primary Endpoints
NASDAQ · 2d ago
Takeda announces zasocitinib studies met primary, secondary endpoints
TipRanks · 2d ago
Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Psoriasis Results
TipRanks · 2d ago
Takeda Canada: British Columbia Now Reimburses FRUZAQLA
NASDAQ · 4d ago
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Seeking Alpha · 5d ago
Weekly Report: what happened at TKPHF last week (1208-1212)?
Weekly Report · 5d ago
Grifols: Positive/Neutral Scenario Posits An Upside
Seeking Alpha · 12/08 17:02
Weekly Report: what happened at TKPHF last week (1201-1205)?
Weekly Report · 12/08 10:08
Takeda and Protagonist Showcase Promising Rusfertide Results at ASH 2025
TipRanks · 12/07 23:52
Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
TipRanks · 12/07 17:00
Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera
NASDAQ · 12/06 16:48
Ascentage Pharma To Launch Global Phase III Study Of Olverembatinib In Ph+ ALL
NASDAQ · 12/05 08:05
Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies
NASDAQ · 12/05 01:43
Weekly Report: what happened at TKPHF last week (1124-1128)?
Weekly Report · 12/01 10:04
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
Seeking Alpha · 11/27 12:20
Weekly Report: what happened at TKPHF last week (1117-1121)?
Weekly Report · 11/24 10:08
FDA investigating death following Adzynma treatment
TipRanks · 11/21 14:15
More
Webull provides a variety of real-time TKPHF stock news. You can receive the latest news about Takeda Pharmaceutical Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About TKPHF
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.